FDA
-
-
-
-
-
-
-
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Ne
-
-
-
-
-
-
-
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initia
-
-
-
-
-
-
-
Zai Lab (ZLAB) Receives U.S. FDA Fast Track Designation for ZL-1310
-
-
-
-
-
-
-
Zai Lab Limited (ZLAB) Receives Orphan Drug Designation from the U.S. FDA for ZL-1310
-
-
-
-
-
-
-
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
-
330,680 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

